Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Mar 10;3(3):CD001703.
doi: 10.1002/14651858.CD001703.pub4.

Antidepressants for low back pain and spine-related leg pain

Michael C Ferraro  1   2 , Donna M Urquhart  3 , Giovanni E Ferreira  4   5 , Michael A Wewege  1   2 , Christina Abdel Shaheed  6 , Adrian C Traeger  4   5 , Jan L Hoving  7 , Eric J Visser  8 , James H McAuley  1   2 , Aidan G Cashin  1   2
Affiliations
Meta-Analysis

Antidepressants for low back pain and spine-related leg pain

Michael C Ferraro et al. Cochrane Database Syst Rev. .

Abstract

Background: Antidepressants are commonly used to treat low back pain and spine-related leg pain. However, their benefits and harms are uncertain. This is an update of a 2008 Cochrane review of antidepressants for non-specific low back pain.

Objectives: To assess the benefits and harms of antidepressants for non-specific low back pain and spine-related leg pain.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform, and EU Clinical Trials Register from inception to 14 November 2024.

Selection criteria: We included randomised controlled trials that compared antidepressants with placebo, usual care, or no treatment/waiting list. Participants were 18 years of age or older with non-specific low back pain or spine-related leg pain of any duration. We excluded participants with low back pain due to spinal fracture, inflammatory disease, aortic dissection, malignancy, or infection. Primary outcomes were pain intensity and disability, measured at short-term follow-up (> 4 to 14 weeks post-randomisation), and total adverse events. Secondary outcomes were serious adverse events, withdrawals due to adverse events, depressive symptoms, and health-related quality of life.

Data collection and analysis: Two review authors independently screened records to determine study inclusion, extracted data, and evaluated risk of bias using RoB 1 tool. Where possible, we conducted meta-analyses. We used GRADE to assess the certainty of evidence.

Main results: We included 26 randomised controlled trials. Eighteen studies included 2535 participants with non-specific low back pain, seven studies included 329 participants with spine-related leg pain, and one study included 68 participants with either condition. Most participants had pain lasting more than three months, with a mean duration between 18 months and 20 years. Mean ages ranged from 27 to 59 years. Studies evaluated serotonin and norepinephrine reuptake inhibitors (SNRIs; eight studies), selective serotonin reuptake inhibitors (SSRIs; two studies), tricyclic antidepressants (TCAs; 14 studies), tetracyclic antidepressants (TeCAs; two studies), or 'other antidepressants' (two studies). All studies were placebo-controlled. Outcomes were measured at short-term follow-up in 73% of studies. All included studies had at least one domain judged at high risk of bias, with 69% at high risk of attrition bias. Non-specific low back pain (benefits) Moderate-certainty evidence demonstrated that SNRIs probably have a small effect on pain intensity (mean difference (MD) (0 to 100 scale) -5.25, 95% confidence interval (CI) -7.17 to -3.34; I2 = 0; 4 studies, 1415 participants) and a trivial effect on disability (MD (0 to 24 scale) -0.91, 95% CI -1.30 to -0.51; I2 = 0; 4 studies, 1348 participants) at short-term follow-up. Low-certainty evidence showed that SSRIs may have little to no effect on pain intensity (MD 1.20, 95% CI -4.90 to 7.30; I2 = 0; 3 studies, 199 participants) and disability (MD -2.20 (0 to 100 scale), 95% CI -8.11 to 3.71; 1 study, 92 participants) at short-term follow-up. Moderate-certainty evidence demonstrated that TCAs probably have little to no effect on pain intensity (MD -2.00, 95% CI -7.25 to 3.24; I² = 31%; 4 studies, 417 participants), but probably have a small effect on disability (MD (0 to 24 scale) -1.76, 95% CI -2.70 to -0.82; I2 = 0; 3 studies, 330 participants) at short-term follow-up. The effects of TeCAs (MD -4.50, 95% CI -17.59 to 8.59; 1 study, 52 participants) and other antidepressants (MD -5.40, 95% CI -23.08 to 12.28; 1 study, 39 participants) on pain intensity at short-term follow-up are unclear (very low-certainty evidence). No studies assessed the effects of TeCAs or other antidepressants on disability. Spine-related leg pain (benefits) The effects of SNRIs on pain intensity (MD -46.10, 95% CI -89.29 to -2.91; 1 study, 11 participants) and disability (MD (0 to 100 scale) -4.40, 95% CI -20.25 to 11.45; 1 study, 11 participants) at short-term follow-up are very uncertain (very low-certainty evidence). Low-certainty evidence showed TCAs may have a large effect on pain intensity at short-term follow-up (MD -23.00, 95% CI -32.12 to -13.88; 1 study, 60 participants), and a moderate effect on disability (MD (0 to 100 scale) -13.00, 95% CI -19.42 to -6.58; 1 study, 60 participants). There were no studies that assessed the effects of SSRIs, TeCAs, or other antidepressants in people with spine-related leg pain. Non-specific low back pain and spine-related leg pain (harms) Moderate-certainty evidence demonstrated that SNRIs probably increase the risk of adverse events (risk ratio (RR) 1.17, 95% CI 1.07 to 1.27; I2 = 0%; 5 studies, 1510 participants), but it is unclear whether they increase the risk of serious adverse events (Peto odds ratio (OR) 1.75, 95% CI 0.79 to 3.89; 5 studies, 1510 participants; very low-certainty evidence). It is unclear whether TCAs increase the risk of adverse events (RR 1.76, 95% CI 0.79 to 3.90; 7 studies, 474 participants; low-certainty evidence) or serious adverse events (Peto OR 6.64, 95% CI 0.41 to 106.72; I² = 0%; 1 study, 142 participants; very low-certainty evidence). It is unclear whether SSRIs (RR 1.83, 95% CI 0.14 to 24.19; I² = 95%; 2 studies, 107 participants; very low-certainty evidence) or TeCAs increase the risk of adverse events (RR 0.93, 95% CI 0.79 to 1.09; 1 study, 52 participants; very low-certainty evidence). No studies assessed the risk of serious adverse events for these classes. No studies measured total adverse events for other antidepressants. It is unclear whether other antidepressants increase the risk of serious adverse events (Peto OR 0.90, 95% CI 0.16 to 4.96; 1 study, 42 participants; very low-certainty evidence).

Authors' conclusions: We found that in people with non-specific low back pain, SNRIs probably have small effects on pain intensity, trivial effects on disability, and are probably associated with adverse effects. TCAs probably do not reduce low back pain intensity, but may have a small effect on disability. The effects of antidepressants on spine-related leg pain are uncertain, though SNRIs and TCAs might be prioritised over other classes for future investigations. Evidence for the safety of SSRIs, TCAs, TeCAs, and other antidepressants in non-specific low back pain and spine-related leg pain remains unclear.

PubMed Disclaimer

Conflict of interest statement

MF is a sign‐off editor for Cochrane but was not involved in the editorial process for this review. He receives a stipend from an Australian Research Training Program grant and Neuroscience Research Australia.

DU reports being an author on a study (funded by National Health and Medical Research Council, Australia, ID 1024401) that was eligible for inclusion in this review but was not involved in selection, data extraction, and assessment of risk of bias and the certainty of evidence involving this study. DU is an editor for Cochrane but was not involved in the editorial process for this review. DU receives salary support from the National Health and Medical Research Council of Australia and Medical Research Future fund grants.

GF reports being an author of an ongoing study that was eligible for inclusion in this review but was not involved in selection and data extraction involving this study. GF received salary support from a National Health and Medical Research Council of Australia grant.

MW received salary support from a National Health and Medical Research Council of Australia grant, Neuroscience Research Australia, and University of New South Wales.

CAS received salary support from a National Health and Medical Research Council of Australia grant and is employed by the University of Sydney.

AT receives grant support from the National Health and Medical Research Council of Australia.

JH is an editor for Cochrane but was not involved in the editorial process for this review.

EV is an investigator on a National Health and Medical Research Council of Australia grant.

JM receives salary support from a National Health and Medical Research Council of Australia grant.

AC receives salary support from a National Health and Medical Research Council of Australia grant and is employed by the University of New South Wales.

Update of

References

References to studies included in this review

Afilal 2020 {published and unpublished data}
    1. Afilal S. Efficacy of clomipramine for chronic lumbar radicular pain a randomized clinical trial (Medical specialisation dissertation). Rabat (Morocco): Mohammed V University Faculty of Medicine and Pharmacy, 2020.
    1. Afilal SA, Fellous S, Ilham A, Abouqal R, Hmamouchi I, Alami N, et al. Efficacy of clomipramine for chronic lumbar radicular pain a randomized clinical trial. Annals of the Rheumatic Diseases 2020;79:59. [DOI: 10.1136/annrheumdis-2020-eular.4373] - DOI
    1. PACTR202001764151121. Efficacy of clomipramine for chronic lumbar radicular pain: a randomized clinical trial. trialsearch.who.int/Trial2.aspx?TrialID=PACTR202001764151121 (first posted 6 November 2019).
Alcoff 1982 {published data only}
    1. Alcoff J, Jones E, Rust P, Newman R. Controlled trial of imipramine for chronic low back pain. Journal of Family Practice 1982;14:841-6. - PubMed
Atkinson 1998 {published data only}
    1. Atkinson HJ, Slater MA, Williams RA, Zisook S, Patterson TL, Grant I, et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain 1998;76:287-96. - PubMed
Atkinson 1999 {published data only}
    1. Atkinson JH, Slater MA, Wahlgren DR, Williams RA, Zisook S, Pruitt SD, et al. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain 1999;83:137-45. - PubMed
Atkinson 2007 {published data only (unpublished sought but not used)}
    1. Atkinson JH, Slater MA, Capparelli EV, Wallace MS, Zisook S, Abramson I, et al. Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain. Journal of Clinical Psychopharmacology 2007;27(2):135-42. - PubMed
    1. NCT00018200. Effect of antidepressants on back pain. clinicaltrials.gov/study/NCT00018200 (first posted 23 June 2005).
Dickens 2000 {published data only (unpublished sought but not used)}
    1. Dickens C, Jayson M, Sutton C, Creed F. The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain. Psychosomatics 2000;41:490-9. - PubMed
    1. GlaxoSmithKline. A double-blind study comparing the efficacy and tolerability of paroxetine and placebo in hospital out-patients with depressive symptoms associated with chronic back pain. www.gsk.com/media/1543/depression_701_full.pdf 2001.
Goodkin 1990 {published data only}
    1. Goodkin K, Gullion CM, Agras WS. A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome. Journal of Clinical Psychopharmacology 1990;10:269-78. - PubMed
Gould 2020 {published data only (unpublished sought but not used)}
    1. Gould HM, Atkinson JH, Chircop-Rollick T, D'Andrea J, Garfin S, Patel SM, et al. A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain. Pain 2020;161(6):1341-9. [DOI: 10.1097/j.pain.0000000000001834] - DOI - PubMed
    1. NCT00964886. Efficacy of antidepressants in chronic back pain. clinicaltrials.gov/study/NCT00964886 (first posted 24 August 2009).
Jenkins 1976 {published data only}
    1. Jenkins DG, Ebbutt AF, Evans CD. Tofranil in the treatment of low back pain. Journal of International Medical Research 1976;4:28-40. - PubMed
Johnson 2011 {published and unpublished data}
    1. Chatterjee N, Noor N, Crowell A, Mackey S. Duloxetine and placebo alter different gray matter regions in chronic low back pain patients. Journal of Pain 2010;11(4 Suppl 1):S40.
    1. Johnson K, Chatterjee N, Noor N, Crowell A, McCue R, Mackey S. Effects of duloxetine and placebo in patients with chronic low back pain. Journal of Pain 2011;12(4 Suppl 1):49.
    1. NCT00388414. Imaging study of chronic low back pain in patients taking pain medication. clinicaltrials.gov/study/NCT00388414 (first posted 13 October 2010).
Katz 2005 {published data only}
    1. Katz J, Pennella-Vaughan J, Hetzel RD, Kanazi GE, Dworkin RH. A randomised, placebo-controlled trial of bupropion sustained release in chronic low back pain. Journal of Pain 2005;6(10):656-61. - PubMed
Khoromi 2007 {published data only}
    1. Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain 2007;130(1-2):66-75. [DOI: 10.1016/j.pain.2006.10.029] - DOI - PMC - PubMed
Konno 2016 {published and unpublished data}
    1. Konno S, Oda N, Ochiai T, Alev L. Randomized, double-blind, placebo-controlled phase III trial of duloxetine monotherapy in Japanese patients with chronic low back pain. Spine 2016;41(22):1709–17. [DOI: 10.1097/BRS.0000000000001707] - DOI - PMC - PubMed
    1. NCT01855919. A study of duloxetine (LY248686) in participants with chronic low back pain. clinicaltrials.gov/study/NCT01855919 (first posted 14 May 2013).
    1. jRCT2080222083. A phase 3 clinical trial of duloxetine in patients with chronic low back pain. jrct.niph.go.jp/en-latest-detail/jRCT2080222083 (first posted 15 May 2013).
Kurniawati 2020 {published data only}
    1. Kurniawati N, Suharjanti I, Hamdan M, Rahardjo JE, Ardiansyah D, Hidayati HB. Efficacy of acetaminophen plus amitriptyline compared to acetaminophen to reduce pain intensity in nonspecific chronic lower back pain. Indian Journal of Forensic Medicine & Toxicology 2020;14(2):1819-25. [DOI: 10.37506/ijfmt.v14i2.3202] - DOI
Marks 2014 {published and unpublished data}
    1. Marks DM, Pae CU, Patkar AA. A double-blind, placebo-controlled, parallel-group pilot study of milnacipran for chronic radicular pain (sciatica) associated with lumbosacral disc disease. Primary Care Companion for CNS Disorders 014;16(4):26268. [DOI: 10.4088/PCC.14m01658] - DOI - PMC - PubMed
    1. NCT01777581. Milnacipran for lumbosacral radicular pain. clinicaltrials.gov/study/NCT01777581 (first posted 24 January 2013).
NCT01225068 {unpublished data only}
    1. NCT01225068. Effect of milnacipran in chronic neuropathic low back pain. clinicaltrials.gov/ct2/show/NCT01225068 (first posted 19 October 2010).
Pheasant 1983 {published data only}
    1. Pheasant H, Bursk A, Goldfarb J, Azen SP, Weiss JN, Borelli L. Amitriptyline and chronic low-back pain. A randomized double-blind crossover study. Spine 1983;8:552-7. - PubMed
Pirbudak 2003 {published data only}
    1. Pirbudak L, Karakurum G, Satana T, Karadasli H, Topalhan M, Oner U, et al. Epidural steroid injection and amitriptyline in the management of acute low back pain originating from lumbar disc herniation [Dysk hernysy kaynakli akut dyskojenyk bel adrilarinda epydural steroyd enjeksyyonu ve amytryptlyn kullanimi]. Artroplasty Artroskopyk Cerrahy [Journal of Arthroplasty & Arthroscopic Surgery] 2003;14(2):89-93.
Schliessbach 2018 {published data only (unpublished sought but not used)}
    1. NCT01179828. Linking altered central pain processing and genetic polymorphism to drug efficacy in chronic low back pain (prediction). clinicaltrials.gov/study/NCT01179828 (first posted 10 August 2010).
    1. Schliessbach J, Siegenthaler A, Bütikofer L, Limacher A, Juni P, Vuilleumier PH, et al. Effect of single-dose imipramine on chronic low-back and experimental pain. PLoS One 2018;13(5):e0195776. [DOI: 10.1371/journal.pone.0195776] - DOI - PMC - PubMed
Schukro 2016 {published data only (unpublished sought but not used)}
    1. 2009-012713-22. Randomized double-blind study comparing the efficacy of duloxetine with placebo in patients with chronic low back pain. clinicaltrialsregister.eu/ctr-search/search?query=2009-012713-22 (first posted 14 October 2010).
    1. NCT01166048. Comparison of the efficacy of duloxetine with placebo in patients with chronic low back pain with a radicular component. clinicaltrials.gov/study/NCT01166048 (first posted 19 July 2010).
    1. Schukro RP, Oehmke MJ, Geroldinger A, Heinze G, Kress HG, Pramhas S. Efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial. Anesthesiology 2016;124(1):150-8. [DOI: 10.1097/ALN.0000000000000902] - DOI - PubMed
Skljarevski 2009a {published and unpublished data}
    1. NCT00408876. Duloxetine versus placebo in chronic low back pain. clinicaltrials.gov/study/NCT00408876 (first posted 6 December 2006).
    1. Skljarevski V, Ossanna M, Liu-Seifert H, Zhang Q, Chappell A, Iyengar S, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. European Journal of Neurology 2009;16(9):1041-8. - PubMed
Skljarevski 2010a {published and unpublished data}
    1. EUCTR2006-003484-31. Effect of duloxetine 60 mg to 120 mg once daily in patients with chronic low back pain. clinicaltrialsregister.eu/ctr-search/search?query=2006-003484-31 (first posted 4 October 2006).
    1. NCT00424593. Duloxetine versus placebo in chronic low back pain. clinicaltrials.gov/study/NCT00424593 (first posted 17 January 2007).
    1. Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS, Detke MJ, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine 2010;35(13):E578-85. [DOI: 10.1097/BRS.0b013e3181d3cef6] - DOI - PubMed
    1. Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS, Detke MJ, et al. Efficacy of duloxetine in chronic low back pain. European Journal of Neurology 2008;15(Suppl 3)(320):P2447.
Skljarevski 2010b {published and unpublished data}
    1. EUCTR2009-012713-22. Randomized double-blind study comparing the efficacy of duloxetine with placebo in patients with chronic low back pain. clinicaltrialsregister.eu/ctr-search/trial/2009-012713-22/AT (first posted 14 April 2010).
    1. NCT00767806. A study for patient with chronic low back pain. clinicaltrials.gov/study/NCT00767806 (first posted 6 October 2008).
    1. NL-OMON32370. Effect of duloxetine 60 mg once daily versus placebo in patients with chronic low back pain. onderzoekmetmensen.nl/en/trial/32370 (first posted 26 June 2008).
    1. Skljarevski V, Zhang S, Desaiah D, Alaka KJ, Palacios S, Miazgowski T, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. Journal of Pain 2010;11(12):1282-90. [DOI: 10.1016/j.jpain.2010.03.002] - DOI - PubMed
    1. Skljarevski V, Zhang S, Desaiah D, Palacios S, Miazgowski T, Patrick K. (248) Efficacy and safety of duloxetine 60 mg once-daily in patients with chronic low back pain. Journal of Pain 2010;11:s38. - PubMed
Treves 1991 {published data only}
    1. Treves R, Montane De La Roque P, Dumond JJ, Bertin P, Arnaud M, Desproges-Gotteron R. Prospective study of the analgesic action of clomipramine versus placebo in refractory low back pain and sciatica (68 cases) [Étude prospective de l'action antalgique de la clomipramine versus placebo dans les lombosciatalgies rebelles (68 cas)]. Revue du Rhumatisme et des Maladies Osteo-articulaires 1991;58:549-52. - PubMed
Urquhart 2018 {published and unpublished data}
    1. ACTRN12612000131853. Is amitriptyline effective in the management of chronic low back pain? [Is low dose amitriptyline more effective than an active placebo in the management of chronic low back pain? A double-blind, randomized, placebo-controlled trial]. anzctr.org.au/Trial/Registration/TrialReview.aspx?id=361972&isReview... (first posted 25 January 2012).
    1. Urquhart D, Wluka A, Van Tulder M, Heritier S, Forbes A, Fong C, et al. Efficacy of low-dose amitriptyline for chronic low back pain: a double-blind, randomised controlled trial. Osteoarthritis and Cartilage 2018;26:s416.
    1. Urquhart DM, Wluka AE, Sim MR, Tulder M, Forbes A, Gibson SJ, et al. Is low-dose amitriptyline effective in the management of chronic low back pain? Study protocol for a randomised controlled trial. Trials 2016;17(514):1-8. [DOI: 10.1186/s13063-016-1637-1] - DOI - PMC - PubMed
    1. Urquhart DM, Wluka AE, Van Tulder M, Heritier S, Forbes A, Fong C, et al. Efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial. JAMA Internal Medicine 2018;178(11):1474-81. [DOI: 10.1001/jamainternmed.2018.4222] - DOI - PMC - PubMed
Vanelderen 2015 {published data only}
    1. Gelijkens V, Van Zundert J, De Vooght P, Vander Laenen M, Heylen R, Vanelderen, P. The effectiveness of amitriptyline in the treatment of subacute lumbar radicular pain. European Journal of Anaesthesiology 2014;52:232.
    1. NCT01869907. Effect of minocycline on pain caused by nerve damage [Effect of minocycline on neuropathic pain]. clinicaltrials.gov/study/NCT01869907 (first posted 2 June 2013).
    1. Vanelderen P, Van Zundert J, Kozicz T, Puylaert M, De Vooght P, Mestrum R, et al. Effect of minocycline on lumbar radicular neuropathic pain: a randomized, placebo-controlled, double-blind clinical trial with amitriptyline as a comparator. Anesthesiology 2015;122(2):399-406. [DOI: 10.1097/ALN.0000000000000508] - DOI - PubMed

References to studies excluded from this review

Brannan 2005 {published data only}
    1. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. Journal of Psychiatric Research 2005;39(1):43-53. - PubMed
Chrzanowski 1977 {published data only}
    1. Chrzanowski J. Imipramine in the treatment of chronic sciatic pains [Imipramina w leczeniu przewlekłej rwy kulszowej]. Wiadomosci Lekarskie 1977;30(18):1439-40. - PubMed
Davidson 1994 {published data only}
    1. Davidson JR, France RD. Bupropion in chronic low back pain. Journal of Clinical Psychiatry 1994;55(8):362. - PubMed
DeLomba 2021 {published data only}
    1. DeLomba W, Bernstein M, Basso K, Suárez E, McLean S, Beaudoin F. 231 The tolerability and effectiveness of duloxetine for the prevention of persistent musculoskeletal pain after trauma and injury: a pilot three-group randomized controlled trial. Annals of Emergency Medicine 2021;78:S94. - PMC - PubMed
    1. Strauss DH, Santhanam DR, McLean SA, Beaudoin FL. Study protocol for a randomised, double-blind, placebo-controlled clinical trial of duloxetine for the treatment and prevention of musculoskeletal pain: altering the transition from acute to chronic pain (ATTAC pain). BMJ Open 2019;9(3):e025002. [DOI: 10.1136/bmjopen-2018-025002] - DOI - PMC - PubMed
EUCTR2013‐004564‐55‐RO {unpublished data only}
    1. EUCTR2013-004564-55-RO. A randomized, multicenter, double-blind, placebo controlled, parallel study to examine the efficacy and safety of a combination treatment in subjects with chronic low back pain [A randomized, multicenter, double-blind, placebo controlled, parallel study to assess the efficacy and safety of the combined administration of sertraline and lamotrigine in subjects with chronic low back pain]. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-004564-55-RO (first posted 30 May 2014).
Gaynor 2011 {published data only}
    1. Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Hann D. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study. Current Medical Research and Opinion 2011;27(10):1859-67. [DOI: 10.1185/03007995.2011.609540] - DOI - PubMed
Gourlay 1986 {published data only}
    1. Gourlay GK, Cherry DA, Cousins MJ, Love BL, Graham JR, McLachlan MO. A controlled study of a serotonin reuptake blocker, zimelidine, in the treatment of chronic pain. Pain 1986;25(1):35-52. [DOI: 10.1016/0304-3959(86)90006-0] - DOI - PubMed
Hameroff 1982 {published data only}
    1. Hameroff SR, Cork RC, Scherer K. Doxepin effects on chronic pain, depression and plasma opioids. Journal of Clinical Psychiatry 1982;43(8):22-6. - PubMed
Hameroff 1984 {published data only}
    1. Hameroff SR, Weiss JL, Lerman JC, Cork RC, Watts KS, Crago BR, et al. Doxepin's effects on chronic pain and depression: a controlled study. Journal of Clinical Psychiatry 1984;45(3):47-53. - PubMed
Isaac 2003 {published data only}
    1. Isaac M. Double-blind study of venlafaxine in chronic pain. In: 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco (CA). 2003.
Johansson 1979 {published data only}
    1. Johansson F, Von Knorring L. A double-blind controlled study of a serotonin uptake inhibitor (zimelidine) versus placebo in chronic pain patients. Pain 1979;7(1):69-78. [DOI: 10.1016/0304-3959(79)90108-8] - DOI - PubMed
Jørgensen 1984 {published data only}
    1. Jørgensen B, Nørrelund N, Bech P, Jakobsen K. Pain and depressive symptoms in general practice. A controlled study of Anafranil (clomipramine) versus placebo [En koolrolleret undersegelse af anafranil (klomipramin) versus placebo]. Ugeskrift for Læger 1984;146(38):2868-72. - PubMed
Krell 2005 {published data only}
    1. Krell HV, Leuchter AF, Cook IA, Abrams M. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics 2005;46(5):379-84. - PubMed
Loldrup 1989 {published data only}
    1. Loldrup D, Langemark M, Hansen HJ, Olesen J, Bech P. Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study. Psychopharmacology 1989;99(1):1-7. [DOI: 10.1007/BF00634443] - DOI - PubMed
McQuay 1992 {published data only}
    1. McQuay JH, Carroll D, Glynn CJ. Low dose amitriptyline in the treatment of chronic pain. Anaesthesia 1992;47(8):646-52. [DOI: 10.1111/j.1365-2044.1992.tb02383.x] - DOI - PubMed
McQuay 1993 {published data only}
    1. McQuay HJ, Carroll D, Glynn CJ. Dose-response for analgesic effect of amitriptyline in chronic pain. Anaesthesia 1993;48(4):281-5. [DOI: 10.1111/j.1365-2044.1993.tb06943.x] - DOI - PubMed
NCT01119924 {unpublished data only}
    1. NCT01119924. A clinical study for assessment of the efficacy and safety of mirtazapine (Smilon) in depression patients with pain. clinicaltrials.gov/study/NCT01119924 (first posted 7 May 2010).
NCT01288937 {unpublished data only}
    1. NCT01288937. A placebo controlled, randomized, double blind trial of milnacipran for the treatment of idiopathic neuropathy pain. clinicaltrials.gov/study/NCT01288937 (first posted 2 February 2011).
Pilowsky 1982 {published data only}
    1. Pilowsky I, Hallett EC, Bassett DL, Thomas PG, Penhall RK. A controlled study of amitriptyline in the treatment of chronic pain. Pain 1982;14:169-79. [DOI: 10.1016/0304-3959(82)90097-5] - DOI - PubMed
Pilowsky 1990 {published data only}
    1. Pilowsky I, Barrow GC. A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain. Pain 1990;40(1):3-19. [DOI: 10.1016/0304-3959(90)91045-K] - DOI - PubMed
Skljarevski 2009b {published data only}
    1. Skljarevski V, Zhang S, Chappell AS, Detke MJ, Murray I, Backonja M. Maintenance of effect of duloxetine in patients with chronic low back pain. European Journal of Neurology 2009;16(Suppl 3):92.
Skljarevski 2010c {published data only}
    1. Skljarevski V, Bair MJ, Ossanna MJ, Frakes E, Zhang S, Alaka K. OMERACT responder analysis of patients treated with duloxetine for chronic low back pain. Arthritis and Rheumatism 2010;62(10):S73-4.
Skljarevski 2010d {published data only}
    1. Skljarevski V, Zhang S, Chappell AS, Walker DJ, Murray I, Backonja M. Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study. Pain Medicine 201;11(5):648-57. [DOI: 10.1111/j.1526-4637.2010.00836.x] - DOI - PubMed
Skljarevski 2012 {published data only}
    1. Skljarevski V, Liu P, Zhang S, Ahl J, Martinez JM. Efficacy and safety of duloxetine in patients with chronic low back pain who used versus did not use concomitant nonsteroidal anti-inflammatory drugs or acetaminophen: a post hoc pooled analysis of 2 randomized, placebo-controlled trials. Pain Research and Treatment 2012;2012:296710. [DOI: 10.1155/2012/296710] - DOI - PMC - PubMed
Songer 1996 {published data only}
    1. Songer DA, Schulte H. Venlafaxine for the treatment of chronic pain. American Journal of Psychiatry 1996;153(3):737. - PubMed
Storch 1986 {published data only}
    1. Storch H, Steck P. Anti-depressive medication in the treatment of low back pain: a controlled trial [Begleitende thymoleptische therapie im rahmen einer kontrollierten studie mit maprotilin (ludiomil) bei der behandlung von kreuzschmerzen]. Nervenarzt 1982;53(8):445-50. - PubMed
Tavafian 2014 {published data only}
    1. Tavafian SS, Jamshidi AR, Mohammad K. Treatment of low back pain: randomized clinical trial comparing a multidisciplinary group-based rehabilitation program with oral drug treatment up to 12 months. International Journal of Rheumatic Diseases 2014;17:159-64. - PubMed
Tsuji 2017 {published data only}
    1. Tsuji T, Itoh N, Ochiai T, Konno S. Response to duloxetine in chronic low back pain: exploratory post hoc analysis of a Japanese Phase III randomized study. Journal of Pain Research 2017;10:2157-68. [DOI: 10.2147/JPR.S138172] - DOI - PMC - PubMed
Tyrer 1996 {published data only}
    1. Tyrer S, Lauder J, Michie M, Griffiths H, Charlton J. The effect of trazodone in depressed and non-depressed patients in chronic pain. European Psychiatry 1996;11(4):359s.
Urquhart 2021 {published data only}
    1. Urquhart DM, Wluka AE, Heritier S, Fong C, Wang Y, Cicuttini FM. Effect of low-dose amitriptyline on low back pain with a neuropathic component: a post hoc analysis. Journal of Pain 2010;21(6):899-902. [DOI: 10.1016/j.spinee.2021.01.012] - DOI - PubMed
Usha Rani 1996 {published data only}
    1. An evaluation of antidepressants in rheumatic pain conditions. Usha Rani P, Naidu MU, Prasad VB, Ramesh Kumar Rao T, Shobha JC. Anesthesia & Analgesia 1996;83(2):371-5. - PubMed
Vijayalakshmi 2016 {published data only}
    1. Vijayalakshmi 2016. Efficacy and safety of duloxetine in patients with neuropathic pain. International Journal of Pharmtech Research 2016;9(4):48-53.
Ward 1984 {published data only}
    1. Ward 1984. Antidepressants in concomitant chronic back pain and depression: doxepin and desipramine compared. Journal of Clinical Psychiatry 1984;45(3):54-9. - PubMed
Yucel 2005 {published data only}
    1. Yucel A, Ozyalcin S, Talu GK, Kiziltan E, Yucel B, Andersen OK, et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. Journal of Pain 2005;1(9):407-16. [DOI: 10.1016/j.ejpain.2004.09.009] - DOI - PubMed
Zitman 1990 {published data only}
    1. Zitman FG, Linssen ACG, Edelbroek PM, Stijnen T. Low dose amitriptyline in chronic pain: the gain is modest. Pain 1990;42(1):35-42. [DOI: 10.1016/0304-3959(90)91089-2] - DOI - PubMed

References to studies awaiting assessment

NCT03249558 {unpublished data only}
    1. NCT03249558. Effect of combined morphine and duloxetine on chronic pain (duloxetine). clinicaltrials.gov/study/NCT03249558 (first posted 11 August 2017).

References to ongoing studies

ACTRN12624000919516 {unpublished data only}
    1. ACTRN12624000919516. Duloxetine for chronic sciatica (DREAM): an adaptive randomised placebo-controlled trial [DREAM: an adaptive randomised placebo-controlled trial of duloxetine compared to placebo for reducing leg pain in people with chronic sciatica]. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12624000919516 (first posted 29 July 2024). - PMC - PubMed

Additional references

Abdel Shaheed 2021
    1. Abdel Shaheed C, Blyth F, Furmage AM, Stanaway F. Getting the “balance” right in clinical trials. BMJ 2021;375:n2869. [DOI: 10.1136/bmj.n2869] - DOI - PubMed
Abdel Shaheed 2023
    1. Abdel Shaheed C, Mathieson S, Wilson R, Furmage AM, Maher CG. Who should judge treatment effects as unimportant? Journal of Physiotherapy 2023;69(3):133-5. [DOI: 10.1016/j.jphys.2023.04.001] - DOI - PubMed
Bagg 2020
    1. Bagg MK, O’Hagan E, Zahara P, Wand BM, Hübscher M, Moseley GL, et al. Systematic reviews that include only published data may overestimate the effectiveness of analgesic medicines for low back pain: a systematic review and meta-analysis. Journal of Clinical Epidemiology 2020;124:149-59. [DOI: 10.1016/j.jclinepi.2019.12.006] - DOI - PubMed
Birkinshaw 2023
    1. Birkinshaw H, Friedrich CM, Cole P, Eccleston C, Serfaty M, Stewart G, et al. Antidepressants for pain management in adults with chronic pain: a network meta‐analysis. Cochrane Database of Systematic Reviews 2023, Issue 5. Art. No: CD014682. [DOI: 10.1002/14651858.CD014682.pub2] - DOI - PMC - PubMed
Bogduk 2009
    1. Bogduk N. On the definitions and physiology of back pain, referred pain, and radicular pain. Pain 2009;147:17-9. [DOI: 10.1016/j.pain.2009.08.020] - DOI - PubMed
Center for Scientific Integrity 2018
    1. The Center for Scientific Integrity. Retraction Watch database. Available from: http://retractiondatabase.org/.
Chiarotto 2018
    1. Chiarotto A, Boers M, Deyo RA, Buchbinder R, Corbin TP, Costa LO, et al. Core outcome measurement instruments for clinical trials in nonspecific low back pain. Pain 2018;159(3):481-95. [DOI: 10.1097/j.pain.0000000000001117] - DOI - PMC - PubMed
Chou 2017
    1. Chou R, Deyo R, Friedly J, Skelly A, Hashimoto R, Weimer M, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. Annals of Internal Medicine 2017;166(7):480-93. [DOI: 10.7326/M16-2458] - DOI - PubMed
Cornelius 2022
    1. Cornelius VR, Phillips R. Improving the analysis of adverse event data in randomized controlled trials. Journal of Clinical Epidemiology 2022;144:185-92. [DOI: 10.1016/j.jclinepi.2021.12.023] - DOI - PubMed
Deeks 2023
    1. Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023. Available from https://training.cochrane.org/handbook/archive/v6.4.
Dieleman 2016
    1. Dieleman JL, Baral R, Birger M, Bui AL, Bulchis A, Chapin A, et al. US spending on personal health care and public health, 1996-2013. JAMA 2016;316(24):2627-46. [DOI: 10.1001/JAMA.2016.16885] - DOI - PMC - PubMed
Dionne 2008
    1. Dionne CE, Dunn KM, Croft PR, Nachemson AL, Buchbinder R, Walker BF, et al. A consensus approach toward the standardization of back pain definitions for use in prevalence studies. Spine 2008;33(1):95-103. [DOI: 10.1097/BRS.0b013e31815e7f94] - DOI - PubMed
Dworkin 2008
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005] - DOI - PubMed
FDA 2020
    1. United States Food and Drug Administration. Title 21 - Food and Drugs Chapter I - Food and Drug Administration Department of Health and Human Services Subchapter D - Drugs for Human Use. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?f... (accessed 3 September 2021).
Ferraro 2021
    1. Ferraro MC, Bagg MK, Wewege MA, Cashin AG, Leake HB, Rizzo RR, et al. Efficacy, acceptability, and safety of antidepressants for low back pain: a systematic review and meta-analysis. Systematic Reviews 2021;10(62):1-13. [DOI: 10.1186/s13643-021-01599-4] - DOI - PMC - PubMed
Ferreira 2021
    1. Ferreira GE, McLachlan AJ, Lin CW, Zadro JR, Abdel Shaheed C, O’Keeffe M, et al. Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis. BMJ 2021;372:m4825. [DOI: 10.1136/bmj.m4825] - DOI - PMC - PubMed
Ferreira 2023
    1. Ferreira ML, Luca K, Haile LM, Steinmetz JD, Culbreth GT, Cross M, et al. Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatology 2023;5(6):e316–29. [DOI: 10.1016/S2665-9913(23)00098-X] - DOI - PMC - PubMed
Finnerup 2016
    1. Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DL, Bouhassira D, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain 2016;157(8):1599-606. [DOI: 10.1097/j.pain.0000000000000492] - DOI - PMC - PubMed
Gouveia 2017
    1. Gouveia N, Rodrigues A, Ramiro S, Eusébio M, Machado PM, Canhao H, et al. The use of analgesic and other pain‐relief drugs to manage chronic low back pain: results from a national survey. Pain Practice 2017;17(3):353-65. [DOI: 10.1111/papr.12455] - DOI - PubMed
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 14 November 2024. Available at https://www.gradepro.org.
Hansford 2023
    1. Hansford HJ, Jones MD, Cashin AG, Ostelo RW, Chiarotto A, Williams SA, et al. The smallest worthwhile effect on pain intensity of nonsteroidal anti-inflammatory drugs and exercise therapy for acute and chronic low back pain: a benefit-harm trade-off study. Journal of Physiotherapy 2023;69(4):240-8. [DOI: 10.1016/j.jphys.2023.08.006] - DOI - PubMed
Harmer 2017
    1. Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry 2017;4(45):409-18. [DOI: 10.1016/S2215-0366(17)30015-9] - DOI - PMC - PubMed
Harrisson 2020
    1. Harrisson SA, Ogollah R, Dunn KM, Foster NE, Konstantinou K. Prevalence, characteristics, and clinical course of neuropathic pain in primary care patients consulting with low back-related leg pain. Clinical Journal of Pain 2020;36(11):813-24. [DOI: 10.1097/AJP.0000000000000879] - DOI - PubMed
Health and Social Care Information Centre 2016
    1. Prescribing and Medicines Team Health and Social Care Information Centre. Prescriptions dispensed in the community: England 2005-2015. https://digital.nhs.uk/data-and-information/publications/statistical/pre... (accessed 1 November 2021).
Henssler 2024
    1. Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry 2024;11(7):526-35. [DOI: 10.1016/S2215-0366(24)00133-0] - DOI - PubMed
Higgins 2017
    1. Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from https://training.cochrane.org/handbook/archive/v5.2.
Higgins 2023
    1. Higgins JP, Eldridge S, Li T, editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023. Available from https://training.cochrane.org/handbook/archive/v6.4.
Hirschfeld 2005
    1. Hirschfeld RM, Mallinckrodt C, Lee TC, Detke MJ. Time course of depression-symptom improvement during treatment with duloxetine. Depression and Anxiety 21;4:170-7. [DOI: 10.1002/DA.20071] - DOI - PubMed
Hong 2013
    1. Hong J, Reed C, Novick D, Happich M. Costs associated with treatment of chronic low back pain: an analysis of the UK general practice research database. Spine 2013;38(1):75-82. [DOI: 10.1002/art.34347] - DOI - PubMed
Horowitz 2023
    1. Horowitz MA, Framer A, Hengartner MP, Sørensen A, Taylor D. Estimating risk of antidepressant withdrawal from a review of published data. CNS Drugs 2023;37:143-57. [DOI: 10.1007/s40263-022-00960-y] - DOI - PMC - PubMed
IASP 2012
    1. IASP. Classification of Chronic Pain. Seattle, WA: IASP Press, 2012.
Ivanova 2011
    1. Ivanova JI, Birnbaum HG, Schiller M, Kantor E, Johnstone BM, Swindle RW. Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care. Spine Journal 2011;11(7):622-32. [DOI: 10.1016/j.spinee.2011.03.017] - DOI - PubMed
James 2023
    1. James RJ, Ferguson E. Depression, cognition, and pain: exploring individual, cultural and country-level effects across Europe. Journal of Pain 2023;24(6):1104-15. [DOI: 10.1016/j.jpain.2023.03.006] - DOI - PubMed
Junqueira 2023
    1. Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, et al. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials. BMJ 2023;381:e073725. [DOI: 10.1136/bmj-2022-073725] - DOI - PubMed
Karran 2024
    1. Karran EL, Cashin AG, Barker T, Boyd MA, Chiarotto A, Mohabir V, et al. Development of recommendations for a minimum dataset for Identifying Social factors that Stratify Health Opportunities and Outcomes (ISSHOOs) in pain research. MethodsX 2024;12:102496. [DOI: 10.1016/j.mex.2023.102496] - DOI - PMC - PubMed
Knezevic 2021
    1. Knezevic NN, Candido KD, Vlaeyen JW, Van Zundert J, Cohen SP. Low back pain. Lancet 2021;398(10294):78-92. [DOI: 10.1016/S0140-6736(21)00733-9] - DOI - PubMed
Koes 2006
    1. Koes BW, Van Tulder MW, Thomas, S. Diagnosis and treatment of low back pain. BMJ 2006;332(7555):1430-4. [DOI: 10.1136/bmj.332.7555.1430] - DOI - PMC - PubMed
Koes 2018
    1. Koes BW, Backes D, Bindels PJ. Pharmacotherapy for chronic non-specific low back pain: current and future options. Expert Opinion on Pharmacotherapy 2018;19(6):537-45. [DOI: 10.1080/14656566.2018.1454430] - DOI - PubMed
Kongsted 2015
    1. Kongsted A, Kent P, Hestbaek L, Vach W. Patients with low back pain had distinct clinical course patterns that were typically neither complete recovery nor constant pain. A latent class analysis of longitudinal data. Spine Journal 2015;15(5):885-94. [DOI: 10.1016/j.spinee.2015.02.012] - DOI - PubMed
Konstantinou 2013
    1. Konstantinou K, Hider SL, Jordan JL, Lewis M, Dunn KM, Hay EM. The impact of low back-related leg pain on outcomes as compared with low back pain alone: a systematic review of the literature. Clinical Journal of Pain 2013;29(7):644-54. [DOI: 10.1097/AJP.0b013e31826f9a52] - DOI - PubMed
Kremer 2018
    1. Kremer M, Yalcin I, Goumon Y, Wurtz X, Nexon L, Daniel D, et al. A dual noradrenergic mechanism for the relief of neuropathic allodynia by the antidepressant drugs duloxetine and amitriptyline. Journal of Neuroscience 2018;38(46):9934-54. [DOI: 10.1523/JNEUROSCI.1004-18.2018] - DOI - PMC - PubMed
Lachin 2016
    1. Lachin JM. Fallacies of last observation carried forward analyses. Clinical Trials 2016;13(2):161-8. [DOI: 10.1177/1740774515602688] - DOI - PMC - PubMed
Mafi 2013
    1. Mafi JN, McCarthy EP, Davis RB, Landon BE. Worsening trends in the management and treatment of back pain. JAMA Internal Medicine 2013;173(17):1573-81. [DOI: 10.1001/jamainternmed.2013.8992] - DOI - PMC - PubMed
Mathieson 2018
    1. Mathieson S, Valenti L, Maher CG, Britt H, Li Q, McLachlan AJ, et al. Worsening trends in analgesics recommended for spinal pain in primary care. European Spine Journal 2018;27(5):1136-45. [DOI: 10.1007/s00586-017-5178-4] - DOI - PubMed
Mayo‐Wilson 2023
    1. Mayo-Wilson E, Qureshi R, Li T. Conducting separate reviews of benefits and harms could improve systematic reviews and meta-analyses. Systematic Reviews 2023;12(67):1-5. [DOI: 10.1186/s13643-023-02234-0] - DOI - PMC - PubMed
McCleane 2008
    1. McCleane G. Antidepressants as analgesics. CNS Drugs 2008;22:139-56. [DOI: 10.2165/00023210-200822020-00005] - DOI - PubMed
Micó 2006
    1. Micó JA, Ardid D, Berrocoso E, Eschalier A. Antidepressants and pain. Trends in Pharmacological Sciences 2006;27(7):348-54. [DOI: 10.1016/j.tips.2006.05.004] - DOI - PubMed
Mika 2013
    1. Mika J, Zychowska M, Makuch W, Rojewska E, Przewlocka B. Neuronal and immunological basis of action of antidepressants in chronic pain–clinical and experimental studies. Pharmacological Reports 2013;65(6):1611-21. [DOI: 10.1016/S1734-1140(13)71522-6] - DOI - PubMed
Moher 2010
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. [DOI: 10.1136/bmj.c869] - DOI - PMC - PubMed
Moore 2012
    1. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004] - DOI - PubMed
NICE 2016
    1. National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management; 30 November 2016. Available at https://www.nice.org.uk/guidance/ng59. - PubMed
NICE 2022
    1. National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management; 29 June 2022. Available at https://www.nice.org.uk/guidance/ng222. - PubMed
O'Neill 2014
    1. O'Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, et al. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. Journal of Clinical Epidemiology 2014;67(1):56-64. [DOI: 10.1016/j.jclinepi.2013.08.005] - DOI - PubMed
Oliveira 2018
    1. Oliveira CB, Maher CG, Pinto RZ, Traeger AC, Lin CW, Chenot JF, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. European Spine Journal 2018;27(11):2791-803. [DOI: 10.1007/s00586-018-5673-2] - DOI - PubMed
Orhurhu 2019
    1. Orhurhu V, Olusunmade M, Akinola Y, Urits I, Orhurhu MS, Viswanath O, et al. Depression trends in patients with chronic pain: an analysis of the nationwide inpatient sample. Pain Physician 2019;22:E487-94. - PubMed
Ostelo 2008
    1. Ostelo RW, Deyo RA, Stratford P, Waddell G, Croft P, Von Korff M, et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine 2008;33(1):90-4. [DOI: 10.1097/BRS.0B013E31815E3A10] - DOI - PubMed
Page 2020
    1. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021;372:n160. [DOI: 10.1136/bmj.n71] - DOI - PMC - PubMed
Page 2023
    1. Page MJ, Higgins JP, Sterne JA. Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023. Available from https://training.cochrane.org/handbook/archive/v6.4.
Paoli 1960
    1. Paoli F, Dacourt G, Corsa P. Preliminary note on the action of imipramine in painful conditions [Note préliminaire sur l’action de l’imipramine dans les états douloureux]. Revue Neurologique 1960;2:503-4. - PubMed
Peryer 2023
    1. Peryer G, Golder S, Junqueira D, Vohra S, Loke YK. Chapter 19: Adverse effects. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023. Available from https://training.cochrane.org/handbook/archive/v6.4.
Phillips 2022
    1. Phillips R, Cro S, Wheeler G, Bond S, Morris TP, Creanor S, et al. Visualising harms in publications of randomised controlled trials: consensus and recommendations. BMJ 2022;377:e068983. [DOI: 10.1136/bmj-2021-068983] - DOI - PMC - PubMed
Price 2024
    1. Price MR, Mead KE, Cowell DM, Troutner AM, Barton TE, Walters SA, et al. Medication recommendations for treatment of lumbosacral radiculopathy: a systematic review of clinical practice guidelines. PM&R 2024;16(10):1128-42. [DOI: 10.1002/pmrj.13142] - DOI - PubMed
Qaseem 2017
    1. Qaseem A, Wilt TJ, McLean RM, Forciea MA. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine 2017;166(7):514-30. [DOI: 10.7326/M16-2367] - DOI - PubMed
Qureshi 2022
    1. Qureshi R, Mayo-Wilson E, Li T. Harms in systematic reviews paper 1: an introduction to research on harms. Journal of Clinical Epidemiology 2022;143:186-96. [DOI: 10.1016/j.jclinepi.2021.10.023] - DOI - PMC - PubMed
Rayner 2016
    1. Rayner L, Hotopf M, Petkova H, Matcham F, Simpson A, McCracken LM. Depression in patients with chronic pain attending a specialised pain treatment centre: prevalence and impact on health care costs. Pain 2016;157(7):1472-9. [DOI: 10.1097/j.pain.0000000000000542] - DOI - PMC - PubMed
RevMan 2024 [Computer program]
    1. Review Manager (RevMan). Version 8.11.0. The Cochrane Collaboration, 2024. Available at https://revman.cochrane.org.
Riley 2010
    1. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010;340:c221. [DOI: 10.1136/bmj.c221] - DOI - PubMed
Riley 2011
    1. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342(7804):964-7. [DOI: 10.1136/bmj.d549] - DOI - PubMed
Santesso 2020
    1. Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology 2020;119:126-35. [DOI: 10.1016/j.jclinepi.2019.10.014] - DOI - PubMed
Schmid 2023
    1. Schmid AB, Tampin B, Baron R, Finnerup NB, Hansson P, Hietaharju A, et al. Recommendations for terminology and the identification of neuropathic pain in people with spine-related leg pain. Outcomes from the NeuPSIG working group. Pain 2023;164(8):1693-704. [DOI: 10.1097/j.pain.0000000000002919] - DOI - PMC - PubMed
Schünemann 2023
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023. Available from https://training.cochrane.org/handbook/archive/v6.4.
Sterne 2019
    1. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. [DOI: 10.1136/bmj.l4898] - DOI - PubMed
Urits 2019
    1. Urits I, Peck J, Orhurhu MS, Wolf J, Patel R, Orhurhu V, et al. Off-label antidepressant use for treatment and management of chronic pain: evolving understanding and comprehensive review. Current Pain and Headache Reports 2019;23(66):1-10. [DOI: 10.1007/s11916-019-0803-z] - DOI - PubMed
Vos 2020
    1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396(10258):1204-22. [DOI: 10.1016/S0140-6736(20)30925-9] - DOI - PMC - PubMed
WHO 2022
    1. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2022. https://www.whocc.no/atc_ddd_index/ (accessed 10 February 2022).

References to other published versions of this review

Urquhart 2008
    1. Urquhart D, Hoving JL, Assendelft WJJ, Roland M, Tulder MW. Antidepressants for non-specific low back pain. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No: CD001703. [DOI: 10.1002/14651858.CD001703.pub3] - DOI - PMC - PubMed
Van Tulder 1999
    1. Van Tulder MW, Hienkens E, Roland M, Assendelft WJ. Antidepressants for non‐specific low‐back pain. Cochrane Database of Systematic Reviews 1999, Issue 7. Art. No: CD001703. [DOI: 10.1002/14651858.CD001703] - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources